SCHEMBL30134085

SCHEMBL30134085

CON(C)C(=O)c1ccc(CN2C[C@@H](C)O[C@@H](C)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.44
POLB P06746 1/20 0.43
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 3/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
AGTR1 P30556 1/20 0.41
AGTR2 P50052 1/20 0.41
MLYCD O95822 1/20 0.40
MLNR O43193 1/20 0.40
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
CYP2A13 Q16696 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25062525 0.82 ALDH1A1 (0.47) HDAC6POLBKDM4EALDH1A1NPC1
SCHEMBL31043119 0.81 MEN1 (0.58) HDAC6POLBKDM4EALDH1A1LMNA
SCHEMBL30134141 0.79 HDAC6 (0.50) HDAC6POLBKDM4EALDH1A1NPC1
SCHEMBL1013993 0.79 HDAC6 (0.50) HDAC6POLBKDM4EALDH1A1NPC1
SCHEMBL2279677 0.79 HDAC6 (0.50) HDAC6POLBKDM4EALDH1A1NPC1
SCHEMBL1014491 0.79 HIF1A (0.61) KDM4ENPC1LMNARAB9ASMN1; SMN2
SCHEMBL5101701 0.78 GRM2 (0.50) HDAC6POLBKDM4EALDH1A1NPC1
SCHEMBL31193129 0.78 KDM4E (0.51) POLBKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL1013735 0.77 MLYCD (0.40) HDAC6SMN1; SMN2KMT2AMLYCDMLNR
SCHEMBL1014953 0.77 MLYCD (0.40) HDAC6SMN1; SMN2KMT2AMLYCDMLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 CN disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 US disclosed
EP-4380936-A1 PYRAZOLOPYRIDINONE COMPOUNDS BeiGene, Ltd. (KY) 2024-06-12 EP disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN disclosed
WO-2023011456-A1 PYRAZOLOPYRIDINONE COMPOUNDS BEIGENE, LTD. (KY) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK HDAC6 343/4885POLB 1119/4885KDM4E 2009/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK HDAC6 343/4885POLB 1119/4885KDM4E 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.